|
Tuesday, February 8, 2022 |
|
Oculis 任命 Bastian Dehmel 博士為首席臨床開發官 |
Oculis S.A.(“Oculis”)為一家後期臨床生物醫藥公司,專注於開發創新性眼科治療方法以改善患者的視力和生活。公司宣佈委任 Bastian Dehmel 博士為全球首席臨床開發官 more info >> |
|
Oculis appoints Dr. Bastian Dehmel as Chief Development Officer |
Oculis S.A. ("Oculis"), a late-stage biopharmaceutical company focused on developing transformative ophthalmic treatments to improve the sight and lives of patients, announces the further strengthening of the Company's executive leadership team with the appointment of Dr. Bastian Dehmel as global Chief Development Officer more info >> |
|
Wednesday, January 5, 2022 |
|
Oculis委任丁伟波先生为全球首席营运官兼中国区总经理 |
Oculis S.A.(「Oculis」)为一家临床后期生物医药公司,专注于开发革命性眼科治疗方法以改善患者的视力和生活。 more info >> |
|
Oculis委任丁偉波先生為全球首席營運官兼中國區總經理 |
Oculis S.A.(「Oculis」)為一家臨床後期生物醫藥公司,專注於開發革命性眼科治療方法以改善患者的視力和生活。 more info >> |
|
Oculis appoints Mr. Webb Ding as Global Chief Operating Officer and General Manager (China) |
Oculis S.A. ("Oculis"), a late-stage biopharmaceutical company focused on developing transformative ophthalmic treatments to improve the sight and lives of patients, announces the appointment of Mr. Webb Ding as global Chief Operating Officer and General Manager, China, with effect from February 1, 2022. more info >> |
|
|
|